Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN

Tudor Investment Corp ET AL bought a new stake in LivaNova PLC (NASDAQ:LIVN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 33,332 shares of the company’s stock, valued at approximately $1,746,000. Tudor Investment Corp ET AL owned 0.06% of LivaNova as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. CIBC Bancorp USA Inc. acquired a new stake in LivaNova in the 3rd quarter worth about $304,000. Oberweis Asset Management Inc. acquired a new position in shares of LivaNova during the third quarter valued at approximately $9,743,000. Shelton Capital Management purchased a new position in shares of LivaNova in the third quarter valued at approximately $325,000. Quarry LP purchased a new position in shares of LivaNova in the third quarter valued at approximately $36,000. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of LivaNova by 57.6% in the third quarter. Parkman Healthcare Partners LLC now owns 275,811 shares of the company’s stock worth $14,447,000 after acquiring an additional 100,811 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Stifel Nicolaus set a $80.00 price target on LivaNova in a research report on Wednesday, February 25th. Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Robert W. Baird set a $75.00 price target on shares of LivaNova in a research note on Tuesday, December 16th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and an average price target of $74.78.

LivaNova Price Performance

NASDAQ:LIVN opened at $61.85 on Friday. LivaNova PLC has a one year low of $32.48 and a one year high of $71.92. The stock has a market cap of $3.38 billion, a PE ratio of -13.87 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36. The stock has a 50 day moving average price of $64.91 and a 200 day moving average price of $60.14.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The company had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities research analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.